Recruiting PHASE1 INTERVENTIONAL 1-arm NCT05698459

OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer

A Phase I, Open-label, Dose Escalation Study to Evaluate the Safety ,tolerance and Pharmacokinetics of OH2 Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer

Sponsor: Binhui Biopharmaceutical Co., Ltd.

Conditions Advanced Liver Cancer

Interventions OH2 injection

Updated 5 times since 2023 Last updated: Dec 19, 2024 Started: May 5, 2023 Primary completion: Aug 31, 2025 Completion: Jan 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Advanced Liver Cancer, this trial is actively recruiting participants. The trial is conducted by Binhui Biopharmaceutical Co., Ltd. and has accumulated 5 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Jan 2025 — Present [monthly]

Recruiting PHASE1
Sep 2024 — Jan 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Jun 2023 — Jul 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Feb 2023 — Jun 2023 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Binhui Biopharmaceutical Co., Ltd.

Data source: Binhui Biopharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wuhan, China